FrancophonIA/ELRC3.0 huggingface dataset:
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom high levels of maternally derived antibodies (special type of proteins, received from the mother in the milk, that help the body to fight infection), it is recommended that the first vaccination is given at nine weeks of age.
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom emapiimaga saadud antikehi (valgud, mis aitavad võidelda infektsiooniga), on soovitatav teha esimene süst 9 nädala vanuses.
English: The company that makes Nobivac L4 has agreed that its scientific data can be used for Canigen L4 (‘informed consent').
Estonian: Nobivac L4 tootja on andnud nõusoleku, et tema teaduslikke andmeid tohib kasutada ka Canigen L4 toetuseks (teabel põhineva nõusoleku alusel).
English: Canigen L4 is a veterinary vaccine used to vaccinate dogs from six weeks of age to protect against leptospirosis caused by one of four specific types of Leptospira bacteria.
Estonian: Canigen L4 on veterinaarvaktsiin, mida kasutatakse alates 6-nädalaste koerte vaktsineerimiseks, et kaitsta neid bakteri Leptospira neljast tüübist ühe tekitatava leptospiroosi eest.
English: For some strains of Leptospira, the vaccine also reduces the excretion (shedding) of the bacteria into the urine by the infected dogs, thereby reducing the risk of transmission.
Estonian: Bakterite Leptospira mõne tüve korral vähendab vaktsiin ka bakterite eritumist (ülekandumist) nakatunud koerte uriini, vähendades seega infektsiooni levimise riski.
English: They also showed that the vaccine is safe to give to pregnant bitches.
Estonian: Samuti tõendasid uuringud, et vaktsiin on tiinetele koertele ohutu.
English: A single ‘booster' injection should be given every year to maintain the vaccine's effect.
Estonian: Hiljem tuleb teha kord aastas kordusvaktsineerimine (1 süst), et säilitada vaktsiini toime.
English: The studies showed that the vaccine reduces infection with Leptospira and excretion of the bacteria into the urine.
Estonian: Uuringud tõendasid, et vaktsiin vähendab Leptospira bakterite tekitatud infektsiooni ja bakterite eritumist uriini.
English: For practical information about using Canigen L4, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Canigen L4 kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: When puppies are known to have
Estonian: Kui on teada, et kutsikate organismis on rohkesti
English: What is Canigen L4 and what is it used for?
Estonian: Mis on Canigen L4 ja milleks seda kasutatakse?
English: In the future, if the animals are exposed to these Leptospira bacteria the immune system will be able to respond more quickly.
Estonian: Kui loomad puutuvad Leptospira bakteritega hiljem uuesti kokku, tekivad antikehad kiiremini.
English: Why is Canigen L4 approved?
Estonian: Miks Canigen L4 heaks kiideti?
English: It is not intended to provide practical advice on how to use Canigen L4.
Estonian: Hindamisaruandes ei anta vaktsiini Canigen L4 kasutamise praktilisi nõuandeid.
English: The vaccine is given to dogs as two injections, four weeks apart, under the skin.
Estonian: Vaktsiini manustatakse koertele 2 süstina, teine süst tehakse 4 nädalat pärast esimest.
English: Canigen L4 is a vaccine.
Estonian: Canigen L4 on vaktsiin.
English: When Canigen L4 is given to dogs the animals' immune system recognises the bacteria as ‘foreign' and makes defences against them.
Estonian: Kui koertele manustatakse vaktsiini Canigen L4, peab immuunsüsteem baktereid võõraks ning tekitab nende vastu antikehi.
English: Other information about Canigen L4
Estonian: Muu teave vaktsiini Canigen L4 kohta
English: This is a summary of the European public assessment report (EPAR) for Canigen L4.
Estonian: See on vaktsiini Canigen L4 Euroopa avaliku hindamisaruande kokkuvõte.
English: A mild and temporary increase in body temperature (1°C or less) may occur for a few days after vaccination, with some puppies showing less activity and/or a reduced appetite.
Estonian: Kerge ja mööduv kehatemperatuuri tõus (kuni 1 °C) võib esineda mõne päeva jooksul pärast vaktsineerimist.
English: What are the risks associated with Canigen L4?
Estonian: Mis riskid vaktsiiniga Canigen L4 kaasnevad?
English: The strains of Leptospira bacteria in Canigen L4 are killed (inactivated) so that they do not cause disease.
Estonian: Canigen L4 sisaldab bakteri Leptospira tüvesid, mis on haiguse tekke takistamiseks hävitatud (inaktiveeritud).
English: How is Canigen L4 used?
Estonian: Kuidas Canigen L4 toimib?
English: Canigen L4 is available as a suspension for injection and can only be obtained with a prescription.
Estonian: Vaktsiini Canigen L4 turustatakse süstesuspensioonina ja see on retseptivaktsiin.
English: What benefits of Canigen L4 have been shown in studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Canigen L4 kasulikkus?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Otezla on 15 January 2015.
Estonian: Euroopa Komisjon andis Otezla müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. jaanuaril 2015.
English: A risk management plan has been developed to ensure that Otezla is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Otezla võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Otezla?
Estonian: Mis meetmed võetakse, et tagada Otezla ohutu ja efektiivne kasutamine?
English: The medicine is available as tablets (10, 20 and 30 mg).
Estonian: Otezlat turustatakse tablettidena (10, 20 ja 30 mg).
English: What is Otezla and what is it used for?
Estonian: Mis on Otezla ja milleks seda kasutatakse?
English: The full EPAR and risk management plan summary for Otezla can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Otezla kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Otezla
Estonian: Muu teave Otezla kohta
English: Treatment is started with a dose of 10 mg on day 1 and gradually increased over a week to the recommended dose of 30 mg twice a day.
Estonian: Ravi alustatakse 10 mg annusega 1. päeval ja seda suurendatakse järk-järgult nädala jooksul soovitatud annuseni 30 mg kaks korda ööpäevas.
English: Otezla may be used alone or combined with other DMARDs.
Estonian: Otezlat tohib kasutada üksikravimina või kombinatsioonis muude DMARDravimitega.
English: These usually occur within the first two weeks of treatment, and get better within 4 weeks.
Estonian: Need ilmnevad tavaliselt esimese kahe ravinädala jooksul ja leevenevad 4 nädala jooksul.
English: Otezla must not be used during pregnancy, and women who can become pregnant should use an effective means of contraception during treatment.
Estonian: Otezlat ei tohi kasutada raseduse ajal ning fertiilses eas naised peavad ravi ajal kasutama efektiivset rasestumisvastast vahendit.
English: Why is Otezla approved?
Estonian: Miks Otezla heaks kiideti?
English: Patients who were already taking other so-called ‘small-molecule DMARDs' such as the medicine methotrexate continued this treatment during the study.
Estonian: Patsiendid, kes juba võtsid muid väikesemolekulilisi DMARD-ravimeid, nt metotreksaati, jätkasid seda ravi ka uuringu ajal.
English: Response to treatment should be evaluated regularly and use of Otezla should be reconsidered if there is no improvement after six months.
Estonian: Ravivastust tuleb hinnata regulaarselt ja kui seisund ei parane 6 kuu järel, tuleb Otezla kasutamine üle vaadata.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Otezla's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Otezla kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Although the medicine had not been compared with other authorised treatments, and for psoriatic arthritis X-ray evidence of an effect on the progress of the disease was not available, the mostly mild or moderate side effects and the fact that the medicine could be taken by mouth might make it more acceptable to patients.
Estonian: Kuigi ravimit ei võrreldud muu heakskiidetud raviga ja psoriaatilise artriidi ravis puudusid haiguse kulule avalduvat toimet tõendavad röntgenipildid, võivad enamasti kerged või mõõdukad kõrvalnähud ja ravimi suukaudne võtmine muuta ravimi patsientidele vastuvõetavamaks.
English: For both psoriasis and psoriatic arthritis benefit there was evidence of maintained benefit when treatment was extended (to 32 and 52 weeks respectively).
Estonian: Nii psoriaasi kui ka psoriaatilise artriidi ravis tõestati kasulikkuse püsimine ravi pikendamisel (vastavalt 32 ja 52 nädalale).
English: What are the risks associated with Otezla?
Estonian: Mis riskid Otezlaga kaasnevad?
English: It is not intended to provide practical advice on how to use Otezla.
Estonian: Hindamisaruandes ei anta Otezla kasutamise praktilisi nõuandeid.
English: The main measure of effectiveness was a 20% improvement in a score measuring symptoms such as tender and swollen joints (ACR-20) after 16 weeks of treatment.
Estonian: Efektiivsuse põhinäitaja oli selliseid sümptomeid nagu puutetundlikud ja turses liigesed mõõtva punktisumma (ACR20) 20% paranemine 16-nädalase ravi järel.
English: Otezla contains the active substance apremilast.
Estonian: Otezla sisaldab toimeainena apremilasti.
English: The Committee therefore considered that it was useful as a second-line treatment in patients who do not respond to or cannot use the first-line treatments.
Estonian: Inimravimite komitee pidas ravimit seepärast kasulikuks teise valiku ravina patsientidel, kellele esimese valiku ravi ei mõju või ei sobi.
English: For the full list of all side effects and restrictions with Otezla, see the package leaflet.
Estonian: Otezla kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Otezla, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Otezla omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The other common side effects (which may affect up to 1 in 10 people) are upper respiratory tract infections (colds) and headaches or tension headaches.
Estonian: Muud sagedad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on ülemiste hingamisteede infektsioonid (külmetus) ja peavalud või pingepeavalud.
English: The main measure of effectiveness in both studies was the proportion of patients who ‘responded' to treatment after 16 weeks.
Estonian: Mõlemas uuringus oli efektiivsuse põhinäitaja nende patsientide osakaal, kellel tekkis 16 nädala järel ravivastus.
English: For psoriatic arthritis, Otezla has been compared with placebo in 3 main studies, involving 1,493 patients with active disease despite prior treatment.
Estonian: Psoriaatilise artriidi ravis on Otezlat võrreldud platseeboga kolmes põhiuuringus, kus osales 1493 patsienti, kellel oli varasemast ravist olenemata aktiivne haigus.
English: In psoriasis, Otezla has been investigated in 2 main studies involving a total of 1,257 patients with moderate to severe plaque psoriasis, in which treatment with Otezla was compared with placebo (a dummy treatment).
Estonian: Otezlat on psoriaasi ravis uuritud kahes põhiuuringus, kus osales kokku 1257 mõõduka kuni raske naastulise psoriaasiga patsienti ja kus Otezla-ravi võrreldi platseeboga (näiv ravim).
English: By blocking PDE4, apremilast reduces the level of these cytokines in the body, and so reduces the inflammation and other symptoms of psoriasis and psoriatic arthritis.
Estonian: PDE4 toimet blokeerides vähendab apremilast tsütokiinide sisaldust organismis ning vähendab seetõttu põletikku ja muid psoriaasi ja psoriaatilise artriidi sümptomeid.
English: How is Otezla used?
Estonian: Kuidas Otezlat kasutatakse?
English: Response to treatment was defined as patients having a 75% or more reduction in a symptom score known as Psoriasis Area Severity Index (PASI-75).
Estonian: Ravivastus määratleti nende patsientide osakaaluna, kelle psoriaasist haaratud pinna ja selle raskuse indeksi (Psoriasis Area Severity Index, PASI-75) punktisumma vähenes vähemalt 75% võrra.
English: Otezla is a medicine used to treat adults with:
Estonian: Otezla on ravim, mida kasutatakse järgmiste haigustega täiskasvanute raviks:
English: Of the patients given Otezla in these two studies, 33% (168 of 562) and 29% (79 of 274) responded to treatment.
Estonian: Kummaski uuringus oli ravivastusega patsiente Otezla uuringurühmas 33% (168 patsienti 562st) ja 29% (79 patsienti 274st) ning platseeborühmas 5% (15 patsienti 282st) ja 6% (8 patsienti 137st).
English: The active substance in Otezla, apremilast, blocks the action of an enzyme inside cells called phosphodiesterase 4 (PDE4).
Estonian: Otezla toimeaine apremilast blokeerib ensüümi fosfodiesteraas-4 (PDE4) rakusisese toime.
English: Benefit was seen both in patients taking Otezla alone and those also taking other DMARDs.
Estonian: Kasulikkus tõestati nii ainult Otezlat võtnud patsientidel kui ka muid DMARD-ravimeid võtnud patsientidel.
English: • active psoriatic arthritis (inflammation of the joints associated with psoriasis) in patients who cannot take or who have not responded well enough to other treatments called disease-modifying antirheumatic drugs (DMARDs).
Estonian: • Aktiivne psoriaatiline artriit (psoriaasiga seotud liigesepõletik) patsientidel, kellel ei ole ravi haigust modifitseerivate antireumaatiliste ravimitega (DMARD-ravimitega) mõjunud või kes neid ravimeid kasutada ei saa.
English: For practical information about using Otezla, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Otezla kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Otezla can only be obtained with a prescription and treatment should only be started by a doctor experienced in the diagnosis and treatment of psoriasis or psoriatic arthritis.
Estonian: Otezla on retseptiravim ja ravi sellega peab alustama ainult psoriaasi või psoriaatilise artriidi diagnoosimises ja ravis kogenud arst.
English: This is a summary of the European public assessment report (EPAR) for Otezla.
Estonian: See on ravimi Otezla Euroopa avaliku hindamisaruande kokkuvõte.
English: For more information about treatment with Otezla, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Otezlaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This was achieved in between 32 and 41% of patients given the approved dose of Otezla in the three studies, compared with 18 to 19% of those given placebo.
Estonian: Selle saavutanud patsiente oli kolmes uuringus Otezla soovitatavat annust võtnud patsientidest 32-41% ja platseeborühmas 18-19%.
English: It is used in patients who have not responded to or cannot use other systemic (affecting the whole body) treatments for psoriasis, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A).
Estonian: Seda kasutatakse patsientidel, kellel ei ole mõjunud teised süsteemsed (kogu organismile mõjuvad) psoriaasiravimid, sh tsüklosporiin, metotreksaat ja PUVA (psoraleen ja ultraviolett-A kiirgus) või kes neid ravimeid kasutada ei saa.
English: This enzyme plays a role in triggering the production of messenger molecules in the immune system (the body's natural defences) called cytokines, which are involved in the inflammation and other processes that cause psoriasis and psoriatic arthritis.
Estonian: See ensüüm aitab tekitada immuunsüsteemi (organismi loodusliku kaitsemehhanismi) virgatsaineid tsütokiine, mis on seotud põletiku ning muude psoriaasi ja psoriaatilist artriiti põhjustavate protsessidega.
English: What benefits of Otezla have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Otezla kasulikkus?
English: The most common side effects with Otezla (which may affect more than 1 in 10 people) are effects on the digestive system such as diarrhoea and nausea (feeling sick).
Estonian: Otezla kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on mõju seedeelundkonnale, nt kõhulahtisus ja iiveldus.
English: The CHMP considered that benefit had been shown in psoriasis and psoriatic arthritis.
Estonian: Inimravimite komitee oli seisukohal, et kasulikkus psoriaasi ja psoriaatilise artriidi ravis on tõendatud.
English: Lower doses should be given to patients with severe impairment of kidney function.
Estonian: Raske neerupuudulikkusega patsiendid peavad kasutama väiksemaid annuseid.
English: How does Otezla work?
Estonian: Kuidas Otezla toimib?
English: These signs include:
Estonian: Nähud on muu hulgas järgmised:
English: • regular contractions lasting at least 30 seconds at a rate of at least four every 30 minutes;
Estonian: • regulaarsed kontraktsioonid, mis kestavad vähemalt 30 sekundit ning mis korduvad iga 30 minuti jooksul vähemalt neli korda;
English: atosiban
Estonian: atosibaan
English: The full EPAR for Atosiban SUN can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Atosiban SUN kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is given into a vein in three stages, over a maximum of 48 hours: an initial injection into a vein (6.75 mg), followed by a high-dose infusion (18 mg per hour) over three hours, then a lower dose infusion (6 mg per hour) lasting up to 45 hours.
Estonian: Ravimit Atosiban SUN manustatakse veeni kolmes järgus ja maksimaalselt 48 tunni jooksul: esimesele süstele veeni (6,75 mg) järgneb suure ravimiannusega infusioon (18 mg/h) kolme tunni jooksul ning seejärel väiksema annusega infusioon (6 mg/h), mis kestab kuni 45 tundi.
English: A risk management plan has been developed to ensure that Atosiban SUN is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada ravimi Atosiban SUN võimalikult ohutu kasutamine.
English: The company provided data from the published literature on atosiban.
Estonian: Ettevõte esitas atosibaani kohta avaldatud kirjandusest pärinevad andmed.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Atosiban SUN on 31 July 2013.
Estonian: Euroopa Komisjon andis ravimi Atosiban SUN müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 31. juulil 2013.
English: If contractions come back, treatment with Atosiban SUN can be repeated up to three more times during the pregnancy.
Estonian: Kui kontraktsioonid tekivad taas, tohib ravi ravimiga Atosiban SUN korrata kuni kolm korda raseduse jooksul.
English: What is Atosiban SUN and what is it used for?
Estonian: Mis on Atosiban SUN ja milleks seda kasutatakse
English: What measures are being taken to ensure the safe and effective use of Atosiban SUN?
Estonian: Mis meetmed võetakse, et tagada ravimi Atosiban SUN kasutamise efektiivsus ja ohutus?
English: By blocking the action of oxytocin, Atosiban SUN prevents contractions and causes the womb to relax, helping to delay birth.
Estonian: Blokeerides oksütotsiini toime, ennetab Atosiban SUN kontraktsioone ja põhjustab emaka lõdvestumist, mis aitab sünnitust edasi lükata.
English: No additional studies were needed as Atosiban SUN is a generic medicine that is given by infusion or injection and contains the same active substance as the reference medicine, Tractocile.
Estonian: Lisauuringuid ei olnud vaja, sest Atosiban SUN on infusiooni või süstina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Tractocile.
English: Why is Atosiban SUN approved?
Estonian: Miks Atosiban SUN heaks kiideti?
English: It is used to delay birth in adult women who are 24 to 33 weeks pregnant, when they show signs that they may give birth preterm (prematurely).
Estonian: Ravimit Atosiban SUN kasutatakse sünnituse edasilükkamiseks täiskasvanud naistel, kelle raseduse kestus on 24-33 nädalat ja kellel esinevad enneaegse sünnituse võimalusele viitavad nähud.
English: Because Atosiban SUN is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Atosiban SUN on geneeriline ravim, peetakse ravimi kasulikkust ja riske samadeks mis võrdlusravimil.
English: Oxytocin is the hormone involved in starting contractions of the womb.
Estonian: Oksütotsiin on hormoon, mis osaleb emakakontraktsioonide algatamisel.
English: Atosiban SUN is a ‘generic medicine'.
Estonian: Atosiban SUN on geneeriline ravim.
English: The Committee recommended that Atosiban SUN be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi müügiloa.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Atosiban SUN, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele ravimi Atosiban SUN ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavate ettevaatusmeetmete teave.
English: This means that Atosiban SUN is similar to a ‘reference medicine' already authorised in the European Union (EU) called Tractocile.
Estonian: See tähendab, et Atosiban SUN on sarnane võrdlusravimiga Tractocile, millel juba on Euroopa Liidus müügiluba.
English: The CHMP concluded that, in accordance with EU requirements, Atosiban SUN has been shown to have comparable quality and to be comparable to Tractocile.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Atosiban SUN võrdväärne kvaliteet ja sarnane toime ravimiga Tractocile.
English: Therefore, the CHMP's view was that, as for Tractocile, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Tractocile korral, ületab ravimi Atosiban SUN kasulikkus sellega kaasnevad riskid.
English: The active substance in Atosiban SUN, atosiban, is an antagonist of the natural hormone oxytocin.
Estonian: Ravimi Atosiban SUN toimeaine atosibaan on loodusliku hormooni oksütotsiini antagonist.
English: Treatment with Atosiban SUN should be carried out by a doctor who has experience in the treatment of pre-term labour.
Estonian: Ravi ravimiga Atosiban SUN peab teostama enneaegse sünnituse ravis kogenud arst.
English: For practical information about using Atosiban SUN, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Atosiban SUN kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Atosiban SUN is a medicine that contains the active substance atosiban.
Estonian: Atosiban SUN on ravim, mis sisaldab toimeainena atosibaani.
English: For more information about treatment with Atosiban SUN, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Atosiban SUN toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: How does Atosiban SUN work?
Estonian: Kuidas Atosiban SUN toimib?
English: Other information about Atosiban SUN
Estonian: Muu teave ravimi Atosiban SUN kohta
English: This is a summary of the European public assessment report (EPAR) for Atosiban SUN.
Estonian: See on ravimi Atosiban SUN Euroopa avaliku hindamisaruande kokkuvõte.